Gastrointestinal

Chronic hepatitis C: screening, treatment, and SVR follow-up

Clinical Overview and When to Suspect Chronic Hepatitis C

— 15–30% develop cirrhosis

— Of those with cirrhosis, 1–4% per year develop hepatocellular carcinoma (HCC)

— 1–5% per year develop decompensation (ascites, variceal bleed, encephalopathy)

— Incidental ALT elevation, even mild (ALT often <100 and fluctuates)

— Risk factors: any prior IDU (even once), intranasal cocaine, tattoos in unregulated settings, blood transfusion before 1992, hemodialysis, needle-stick exposure, incarceration history, HIV, MSM with high-risk practices

— Children of HCV-positive mothers (vertical transmission ~6%, doubled if HIV co-infected)

— Extrahepatic clues: mixed cryoglobulinemia, membranoproliferative glomerulonephritis, porphyria cutanea tarda, lichen planus, B-cell non-Hodgkin lymphoma

Board pearl: Chronic HCV is the prototypical "silent" disease — most patients are asymptomatic until cirrhosis develops, which is why universal one-time screening replaced risk-based screening. On Step 3, an asymptomatic adult with mildly elevated transaminases and any subtle risk factor should prompt HCV antibody testing before extensive workup.

Chronic HCV = detectable HCV RNA persisting >6 months after acute infection; ~50–80% of acute cases become chronic because HCV evades immunity via rapid mutation of envelope glycoproteins.

Global health priority: WHO targets HCV elimination by 2030; in the US, ~2.4 million adults are chronically infected, and prevalence is rising in 20–39-year-olds driven by the injection-drug-use epidemic.

Natural history over 20–30 years:

Accelerators of fibrosis: alcohol use, HIV/HBV coinfection, hepatic steatosis (obesity, diabetes), male sex, age >40 at infection, immunosuppression.

When to suspect chronic HCV in primary care:

USPSTF/CDC universal screening (2020): one-time HCV antibody screening for all adults ≥18 years, and screening in every pregnancy. Repeat periodic screening for ongoing risk (active IDU, hemodialysis, HIV+ MSM).

Presentation Patterns and Key History

— Fatigue (most frequent complaint, often dismissed)

— Right upper quadrant discomfort or fullness

— Arthralgias, myalgias

— Poor concentration ("brain fog"), sleep disturbance

— Pruritus, dry eyes/mouth (sicca-like)

— Abdominal distension, lower-extremity edema (ascites)

— Hematemesis or melena (variceal bleeding)

— Confusion, day-night reversal, asterixis (hepatic encephalopathy)

— Weight loss, early satiety (HCC or muscle wasting)

— Easy bruising, gum bleeding (coagulopathy, thrombocytopenia)

— Substance use: lifetime injection-drug use including "experimental" use decades earlier, intranasal drug sharing, current use, willingness to engage in harm reduction

— Alcohol: AUDIT-C screen; any alcohol accelerates fibrosis and is the single biggest modifiable cofactor

— Sexual history: HIV status, MSM with traumatic practices, multiple partners

— Transfusion history: any blood product before July 1992 in the US

— Healthcare exposures: hemodialysis, organ transplant before 1992, unregulated tattoos/piercings, occupational needle-stick

— Birthplace: high-prevalence regions (Egypt, Pakistan, parts of sub-Saharan Africa)

— Family history: mother with HCV (vertical transmission)

— Medication history: prior interferon-based therapy, prior DAA failure, all current meds for drug-drug interaction screening (statins, amiodarone, PPIs, anticonvulsants, HIV ART)

Step 3 management: When you identify HCV in clinic, the visit must include alcohol counseling, hepatitis A and B vaccination if non-immune, harm-reduction counseling for IDU, and partner notification — these are billable, guideline-endorsed elements of the initial HCV visit and frequently tested.

Most chronic HCV patients are asymptomatic — discovered through screening, abnormal LFTs, or evaluation for an extrahepatic manifestation. Symptoms, when present, are nonspecific.

Common subtle symptoms:

Symptoms of advanced disease (cirrhosis/decompensation):

Key history domains (essential for Step 3 vignettes):

Physical Exam Findings (and Hepatic Decompensation Assessment)

— Spider angiomata on upper trunk

— Palmar erythema

— Dupuytren contractures

— Parotid enlargement, gynecomastia, testicular atrophy

— Caput medusae, splenomegaly

— Terry nails (proximal white, distal pink), clubbing

— Muscle wasting of temples and shoulders (sarcopenia — independent mortality predictor)

— Ascites: shifting dullness, fluid wave, bulging flanks

— Jaundice: scleral icterus precedes skin

— Asterixis: flap with wrists extended → hepatic encephalopathy

— Fetor hepaticus

— Lower-extremity edema

— Caput medusae or visible abdominal collaterals (portal hypertension)

— Palpable purpura on lower extremities (cryoglobulinemic vasculitis)

— Lichen planus: violaceous, flat-topped, polygonal papules on wrists/oral mucosa (Wickham striae)

— Porphyria cutanea tarda: photosensitive vesicles, hyperpigmentation, hypertrichosis on dorsal hands

— Sicca symptoms with parotid fullness

— Tachycardia + hypotension + melena in a cirrhotic = variceal bleed until proven otherwise → ICU, IV access ×2, octreotide, ceftriaxone, urgent EGD

— AMS + asterixis → check ammonia is optional; treat empirically with lactulose

— Tense ascites + fever/abdominal pain → diagnostic paracentesis BEFORE antibiotics

CCS pearl: In a CCS case of cirrhotic decompensation, ordering diagnostic paracentesis within the first simulated hour for any cirrhotic admitted with ascites is a high-yield "do not miss" action — SBP must be ruled out (PMN ≥250/µL is diagnostic) before empiric ceftriaxone, but you should order both nearly simultaneously.

Compensated chronic HCV: physical exam is typically normal. This is a Step 3 trap — a normal abdomen does NOT exclude significant fibrosis.

Subtle stigmata of chronic liver disease (suggest cirrhosis even if labs near-normal):

Decompensation findings (signal urgent escalation):

Extrahepatic exam clues to HCV:

Hemodynamic/decompensation triage at the bedside:

Diagnostic Workup — Initial Labs and Confirmatory HCV Testing

— Positive antibody = current OR past (cleared/treated) infection — does not distinguish

— False negatives in immunocompromised (HIV with low CD4, hemodialysis, post-transplant) → if high suspicion, send HCV RNA directly

— False positives possible in autoimmune disease

— Detectable RNA = current chronic infection → treat

— Undetectable RNA after positive antibody = spontaneously cleared or previously treated (still need to counsel re: reinfection risk; antibody does not protect)

— Prior DAA treatment failure

— Decompensated cirrhosis (some regimens genotype-specific)

— CBC with platelets (thrombocytopenia → portal hypertension)

— Comprehensive metabolic panel including ALT, AST, total/direct bilirubin, albumin

— INR/PT (synthetic function)

— HBsAg, anti-HBs, anti-HBc (screen for HBV — risk of HBV reactivation during DAA therapy)

— HIV test

— Hepatitis A IgG (vaccinate if non-immune)

— Pregnancy test in reproductive-age women

— TSH, lipid panel, HbA1c (HCV associated with insulin resistance)

— Non-invasive: FIB-4 (age, AST, ALT, platelets) and APRI — calculated from routine labs; FIB-4 >3.25 suggests advanced fibrosis

— Elastography (FibroScan/transient elastography) preferred when available; >12.5 kPa suggests cirrhosis

— Serum panels (FibroSure)

— Liver biopsy now rarely needed

Board pearl: A positive HCV antibody with undetectable HCV RNA in a treatment-naive patient = spontaneously cleared infection — no treatment, counsel on reinfection risk, no HCC surveillance unless cirrhotic.

Step 1: HCV antibody (anti-HCV) by EIA — the universal screening test.

Step 2: HCV RNA (quantitative PCR) — reflex automatically from positive antibody (current CDC recommendation).

Step 3: HCV genotype — no longer routinely required since pangenotypic DAAs are first-line, but obtained in:

Baseline labs in every newly diagnosed patient:

Fibrosis staging is mandatory before treatment — guides HCC surveillance and regimen choice:

Diagnostic Workup — Advanced and Pre-Treatment Studies

— Clinical: stigmata + splenomegaly + ascites

— Labs: platelets <150K, AST/ALT >1, low albumin, elevated INR/bilirubin

— Imaging: nodular liver contour, splenomegaly, recanalized umbilical vein, ascites on ultrasound

— Elastography ≥12.5 kPa; FIB-4 >3.25

— Biopsy METAVIR F4 (gold standard, rarely needed now)

— Child-Pugh A (compensated, score 5–6): standard DAA regimens, all options available

— Child-Pugh B/C (decompensated): avoid protease inhibitors (glecaprevir, voxilaprevir, grazoprevir) due to hepatotoxicity → use sofosbuvir/velpatasvir ± ribavirin; refer to transplant hepatology

— Ultrasound ± AFP every 6 months

— Continue lifelong — SVR reduces but does not eliminate HCC risk

— EGD at diagnosis; if no varices and compensated, repeat every 2–3 years

— Small varices: repeat in 1–2 years or start nonselective beta-blocker (carvedilol, propranolol, nadolol)

— Medium/large varices: nonselective BB or band ligation

— Baveno VI criteria: platelets >150K and elastography <20 kPa may safely defer EGD

— Statins: many require dose reduction or hold (esp. with glecaprevir/pibrentasvir)

— Amiodarone + sofosbuvir → life-threatening bradycardia, contraindicated

— PPIs reduce ledipasvir absorption

— Anticonvulsants (carbamazepine, phenytoin) → reduce DAA levels, often contraindicated

— HIV ART: efavirenz, tipranavir interactions; review every regimen

Key distinction: Compensated (Child-Pugh A) vs decompensated (B/C) cirrhosis is the single most important branch point in DAA selection — protease inhibitor–containing regimens are contraindicated in decompensated disease.

Cirrhosis assessment drives downstream decisions (surveillance, regimen, duration):

Child-Pugh and MELD scores classify cirrhosis severity:

HCC surveillance required indefinitely in any patient with cirrhosis (even after SVR):

Variceal screening at cirrhosis diagnosis:

Drug-drug interaction check (use HEP Drug Interactions tool, Liverpool):

Renal function (eGFR) and HBV serologies repeated immediately pre-treatment if not recent.

Risk Stratification and Treatment Eligibility

1. Is the patient cirrhotic? (yes/no) — drives surveillance and duration

2. If cirrhotic, is it compensated or decompensated? — drives regimen

3. Has the patient been treated before? (treatment-naïve vs experienced) — drives regimen

4. What are the drug-drug interactions and comorbidities?

— Treatment-naïve, no cirrhosis or compensated cirrhosis: simple pangenotypic regimen, 8–12 weeks; primary care can prescribe

— Treatment-naïve, decompensated cirrhosis: refer to hepatology; sofosbuvir/velpatasvir ± ribavirin 12–24 weeks; transplant evaluation

— Treatment-experienced (prior DAA failure): refer to hepatology; sofosbuvir/velpatasvir/voxilaprevir 12 weeks

— HCV/HIV coinfected: same DAAs but careful ART interaction review

— HCV/HBV coinfected: monitor for HBV reactivation — give entecavir/tenofovir prophylaxis if HBsAg+

— Pregnancy: defer treatment until postpartum (DAAs not yet approved in pregnancy as of current guidance, though emerging data favorable)

— Active IDU is NOT a contraindication — treat concurrent with harm reduction; reinfection risk does not justify withholding

Step 3 management: Active injection drug use does not preclude HCV treatment. Withholding therapy from a person who uses drugs is not guideline-concordant — pair DAA treatment with syringe-service program referral and offer of medications for opioid use disorder (buprenorphine/methadone).

Current AASLD/IDSA guidance: treat virtually everyone with detectable HCV RNA regardless of fibrosis stage, age (≥3 years), or comorbidities — only exclusions are short life expectancy from non-hepatic disease unaltered by treatment.

Pre-treatment risk stratification asks four questions:

Categories of patient for treatment planning:

Special prioritization (not exclusions):

Simplified treatment algorithm (AASLD): for treatment-naïve adults without cirrhosis or with compensated cirrhosis, no HIV, no HBV, no prior liver transplant — primary care providers can prescribe glecaprevir/pibrentasvir or sofosbuvir/velpatasvir without genotype testing.

Pharmacotherapy — Pangenotypic DAA Regimens

— Glecaprevir/pibrentasvir (Mavyret) — NS3/4A PI + NS5A inhibitor

· 8 weeks if no cirrhosis (any genotype, treatment-naïve)

· 8 weeks if compensated cirrhosis (treatment-naïve)

· 3 tablets once daily with food

· Avoid in decompensated cirrhosis (Child-Pugh B/C) — PI hepatotoxicity

— Sofosbuvir/velpatasvir (Epclusa) — NS5B + NS5A inhibitor

· 12 weeks for all (with or without compensated cirrhosis)

· Safe in decompensated cirrhosis (add ribavirin 12 weeks if Child-Pugh B/C)

· Avoid with amiodarone (severe bradycardia)

· PPIs reduce absorption — minimize or separate dosing

— Sofosbuvir/velpatasvir/voxilaprevir (Vosevi) — 12 weeks for DAA-experienced failures

— Fatigue, headache, nausea, insomnia

— Ribavirin (when added): hemolytic anemia (monitor Hgb), teratogenic — strict contraception × 6 months in both sexes

— Amiodarone + sofosbuvir → symptomatic bradycardia/heart block — contraindicated

— Rifampin, carbamazepine, phenytoin, St. John's wort — strong CYP/P-gp inducers, reduce DAA levels, contraindicated

— Statins: rosuvastatin/atorvastatin levels increased with glecaprevir/pibrentasvir — dose reduce or switch to pravastatin

— PPIs + ledipasvir or velpatasvir: reduced absorption — use lowest dose, dose with DAA, or hold

— Ethinyl estradiol + glecaprevir/pibrentasvir: ALT elevations — avoid combined OCPs

Board pearl: The two pangenotypic regimens to memorize are glecaprevir/pibrentasvir (8 weeks, with food) and sofosbuvir/velpatasvir (12 weeks, watch amiodarone and PPIs). Genotype testing is not required to start.

Direct-acting antivirals (DAAs) have replaced interferon entirely. Cure rates (SVR12) >95%, oral, 8–12 weeks, well-tolerated.

First-line pangenotypic regimens (treatment-naïve, no/compensated cirrhosis):

Salvage/retreatment regimen:

Adverse effects (mild):

Critical drug-drug interactions to memorize:

HBV reactivation: screen HBsAg/anti-HBc before DAAs; if HBsAg+, give entecavir or tenofovir during and after DAA therapy.

Treatment Monitoring and Defining Cure (SVR12)

— HCV RNA quantitative, genotype optional

— CBC, CMP including LFTs, INR, eGFR

— HBsAg, anti-HBc, anti-HBs, HIV

— Pregnancy test

— Medication reconciliation with DDI screen

— Cirrhosis staging (FIB-4, elastography)

— Clinical check (phone or in-person) at 4 weeks for adherence, side effects, new medications

— Lab monitoring not required routinely if simplified pathway eligible

— For cirrhotic, HIV, or complex patients: LFTs at 4 weeks; HCV RNA at 4 weeks optional

— Stop and reassess if ALT >10× ULN or symptomatic ALT >ULN with bilirubin/INR rise

— Order quantitative HCV RNA 12 weeks after the last dose

— >95% achieve SVR12 with first-line regimens

— SVR12 essentially equals SVR24 — late relapse <1%

— Relapse: SVR at end of treatment but viremic at 12 weeks → retreat with sofosbuvir/velpatasvir/voxilaprevir

— Non-response / breakthrough: detectable RNA during therapy — suspect non-adherence or resistance

— Reinfection (not failure): SVR12 achieved, then new viremia — sequence different from prior; treat again

— Take with food (glecaprevir/pibrentasvir)

— Do not miss doses

— Avoid alcohol

— Report new prescriptions before starting them

— Continue HCC surveillance if cirrhotic — for life, even after cure

CCS pearl: The defining lab order at the conclusion of HCV treatment is HCV RNA quantitative 12 weeks after the last dose — if undetectable, document SVR12 and the patient is cured. Ordering this prematurely (e.g., at end of treatment) does not establish cure.

Pre-treatment baseline (within 6 months of start):

On-treatment monitoring (simplified algorithm for non-cirrhotic, treatment-naïve):

End of treatment: HCV RNA may still be detectable in some — does not predict failure.

SVR12 (sustained virologic response at 12 weeks post-treatment) = HCV RNA undetectable 12 weeks after completing therapy = virologic cure.

Definitions:

Counseling during treatment:

Special Populations — Elderly and Renal/Hepatic Impairment

— DAAs are safe and effective; age alone is not a contraindication

— Treatment improves survival and quality of life even in octogenarians with reasonable life expectancy

— Watch polypharmacy — comprehensive medication review for DDIs (anticoagulants, antiarrhythmics, statins)

— Slower fibrosis regression after SVR but HCC risk reduction still substantial

— Glecaprevir/pibrentasvir: safe at any eGFR, including hemodialysis — preferred in CKD/ESRD

— Sofosbuvir-based regimens: previously avoided in eGFR <30, but updated FDA labeling now permits sofosbuvir/velpatasvir in severe renal impairment and ESRD

— HCV-associated membranoproliferative glomerulonephritis with cryoglobulinemia: treat HCV; consider rituximab + plasmapheresis for severe disease

— Compensated cirrhosis (Child-Pugh A): standard regimens, full options

— Decompensated cirrhosis (Child-Pugh B/C):

· Protease inhibitors contraindicated (glecaprevir, voxilaprevir, grazoprevir) — hepatotoxicity

· Use sofosbuvir/velpatasvir + weight-based ribavirin × 12 weeks, or sof/vel × 24 weeks if ribavirin intolerant

· Refer to liver transplant center

— HCC: treat HCC first (resection, ablation, TACE, transplant) or concurrently; HCC alone is not a contraindication but may reduce SVR slightly

— Pre-transplant: treat if compensated; if MELD >20 or decompensated, may defer until post-transplant to preserve transplant window

— Post-transplant: treat any time; watch for calcineurin inhibitor (tacrolimus) interactions with PIs

Key distinction: In decompensated cirrhosis, the answer is always sofosbuvir/velpatasvir (± ribavirin) — never a regimen containing a protease inhibitor (the "-previr" suffix). This is one of the most testable safety facts in HCV pharmacology.

Elderly patients (>65 years):

Renal impairment:

Hepatic impairment:

Liver transplant candidates and recipients:

Hemodialysis patients: glecaprevir/pibrentasvir × 8 weeks is the cleanest option.

Special Populations — Pregnancy, Pediatrics, and Coinfections

— Universal screening with HCV antibody recommended in every pregnancy (CDC, ACOG, USPSTF 2020)

— Confirm with HCV RNA if antibody positive

— DAAs are not yet FDA-approved in pregnancy — defer treatment until after delivery (emerging trial data favorable; specialty consultation if treatment considered)

— Ribavirin is teratogenic (Category X) — strictly avoid; contraception ×6 months after for both partners

— Mode of delivery: HCV alone is not an indication for cesarean delivery

— Breastfeeding is permitted unless nipples are cracked/bleeding

— Avoid internal fetal scalp electrodes, prolonged rupture of membranes when possible

— HCV RNA at age 2–6 months (preferred), OR

— HCV antibody at age ≥18 months (maternal antibody clears by then)

— Treat children ≥3 years old with detectable HCV RNA

— Glecaprevir/pibrentasvir and sofosbuvir/velpatasvir approved down to age 3

— Weight-based dosing; same 8–12 week durations

— Faster fibrosis progression — treat all

— Use DAAs; rigorous ART interaction check (avoid efavirenz with some regimens)

— Maintain ART; do not interrupt

— Risk of HBV reactivation with DAA-induced HCV clearance — FDA boxed warning

— If HBsAg positive: start entecavir or tenofovir prophylaxis concurrent with DAAs

— If HBsAg negative, anti-HBc positive: monitor ALT and HBV DNA during/after DAAs

— Treat — do not withhold

— Co-locate with MOUD (buprenorphine, methadone), syringe-service programs

— Reinfection rate ~2–5%/year; rescreen with HCV RNA annually

Board pearl: A pregnant patient newly diagnosed with HCV → counsel, monitor, defer DAA therapy until postpartum, allow vaginal delivery and breastfeeding, and test the infant with HCV RNA at 2–6 months.

Pregnancy:

Vertical transmission: ~6% overall; ~10–12% if HIV coinfection. Test infants:

Pediatrics:

HCV/HIV coinfection:

HCV/HBV coinfection:

People who inject drugs:

Complications and Adverse Outcomes

— Cirrhosis: develops in 15–30% over 20–30 years

— Hepatocellular carcinoma (HCC): 1–4%/year once cirrhotic; HCV is the leading cause of HCC in the US

— Decompensation: ascites, variceal hemorrhage, hepatic encephalopathy, hepatorenal syndrome, spontaneous bacterial peritonitis

— Portal hypertension: splenomegaly, thrombocytopenia, varices, hepatopulmonary syndrome, portopulmonary hypertension

— Acute-on-chronic liver failure: triggered by infection, GI bleed, alcohol

— Mixed cryoglobulinemia (type II): palpable purpura, arthralgias, glomerulonephritis, peripheral neuropathy — most classic extrahepatic association

— Membranoproliferative glomerulonephritis (MPGN): nephrotic/nephritic mixed picture, low C3/C4

— B-cell non-Hodgkin lymphoma (especially marginal zone, splenic) — HCV is an established cause; some regress after SVR

— Porphyria cutanea tarda: photosensitive vesicles on dorsal hands, hypertrichosis

— Lichen planus: oral and cutaneous

— Sicca syndrome (dry eyes/mouth)

— Autoimmune phenomena: thyroid disease, autoimmune hepatitis overlap

— Insulin resistance and type 2 diabetes — accelerated; insulin sensitivity improves after SVR

— Increased cardiovascular events and stroke risk

— Generally mild: fatigue, headache, nausea

— HBV reactivation — boxed warning; screen HBsAg/anti-HBc

— Bradyarrhythmia with sofosbuvir + amiodarone

— Ribavirin: hemolytic anemia, teratogenicity

— Rare hepatic decompensation with PIs in advanced cirrhosis

— HCC risk persists if cirrhotic — lifelong every-6-month surveillance

— Reinfection if ongoing risk behavior

— Established cirrhosis usually does not fully reverse but fibrosis may regress

Key distinction: SVR ≠ cure of cirrhosis. The virus is gone, but cirrhotic patients require lifelong HCC surveillance with ultrasound ± AFP every 6 months.

Hepatic complications:

Extrahepatic manifestations (HCV is highly extrahepatic — frequently tested):

Treatment-related adverse events:

Post-SVR residual risks:

When to Escalate Care — Hepatology Referral and Inpatient Triage

— Decompensated cirrhosis (Child-Pugh B/C, ascites, encephalopathy, varices, jaundice)

— Hepatocellular carcinoma or suspicious lesion on imaging

— Treatment-experienced patient with prior DAA failure

— HIV/HBV coinfection in complex patients (or comfortable PCPs with consult support)

— Pre– or post-liver transplant

— Unusual extrahepatic disease (cryoglobulinemic vasculitis, MPGN, NHL) — also rheum/nephro/heme

— Acute on-treatment hepatotoxicity (ALT >10× ULN or rising bilirubin/INR)

— Suspected HBV reactivation during DAAs

— MELD ≥15

— Any decompensation event (ascites, variceal bleed, encephalopathy, jaundice)

— HCC within Milan criteria (single ≤5 cm or up to 3 lesions each ≤3 cm, no vascular invasion)

— Variceal hemorrhage: ICU; IV access ×2 large-bore; transfuse to Hgb 7; octreotide 50 mcg IV bolus then 50 mcg/hr ×3–5 days; ceftriaxone 1 g IV daily ×7 days (reduces mortality regardless of ascites); EGD with banding within 12 hours; if uncontrolled → TIPS

— SBP: ascitic PMN ≥250/µL → cefotaxime or ceftriaxone; albumin 1.5 g/kg day 1, 1 g/kg day 3 (prevents hepatorenal syndrome)

— Hepatic encephalopathy: identify trigger (infection, GI bleed, dehydration, electrolyte disturbance, sedatives, constipation); lactulose titrated to 2–3 BMs/day; add rifaximin if recurrent

— Hepatorenal syndrome: albumin + midodrine + octreotide (outpatient/floor) or norepinephrine + albumin (ICU); urgent transplant evaluation

— Acute liver failure / acute-on-chronic: transfer to transplant center

CCS pearl: A cirrhotic patient with new ascites admitted to the hospital — order diagnostic paracentesis with cell count, gram stain, culture, albumin, and total protein within the first hour, plus serum albumin to calculate SAAG. Missing this paracentesis is a classic CCS deduction.

Refer to hepatology (cannot be managed in primary care alone):

Liver transplant referral threshold:

Inpatient/ICU triage:

Key Differentials — Other Causes of Chronic Hepatitis

— HBsAg positive >6 months; HBV DNA detectable

— Vertical/sexual/parenteral transmission

— Treatment: entecavir or tenofovir (suppress, not cure)

— Vaccine-preventable; coinfection with HCV worsens fibrosis

— AUDIT-C positive, AST:ALT >2 (often both <300), elevated GGT, macrocytosis

— Imaging: steatosis early, nodular cirrhosis late

— Treatment: abstinence, naltrexone/acamprosate, nutritional support, vaccinations

— Obesity, type 2 diabetes, metabolic syndrome

— Mild ALT elevation, hepatic steatosis on imaging

— Cofactor with HCV — accelerates fibrosis

— Treatment: weight loss, GLP-1 agonists, treat metabolic risk factors; resmetirom for MASH with F2–F3 fibrosis

— Young women, ANA/ASMA/anti-LKM-1 positive, elevated IgG

— Marked ALT/AST elevation

— Treatment: prednisone + azathioprine

— Middle-aged women, pruritus, elevated alkaline phosphatase, anti-mitochondrial antibody (AMA)

— Treatment: ursodeoxycholic acid; obeticholic acid if inadequate response

— Associated with IBD (especially UC); MRCP shows beading; p-ANCA often positive

— Increased risk of cholangiocarcinoma

— HFE gene C282Y homozygote; elevated ferritin and transferrin saturation >45%

— Treatment: therapeutic phlebotomy

— Age <40, low ceruloplasmin, Kayser-Fleischer rings, neuropsychiatric symptoms

— Treatment: chelation (penicillamine, trientine), zinc

Key distinction: In a patient with chronic transaminitis, send a screening panel: HCV antibody, HBsAg/anti-HBc, ferritin/iron saturation, ANA/ASMA/IgG, AMA, ceruloplasmin (if <40), alpha-1 antitrypsin, plus ultrasound. Don't stop at one diagnosis — HCV often coexists with steatosis and alcohol use.

Chronic hepatitis B (HBV):

Alcohol-associated liver disease:

Metabolic dysfunction–associated steatotic liver disease (MASLD, formerly NAFLD):

Autoimmune hepatitis (AIH):

Primary biliary cholangitis (PBC):

Primary sclerosing cholangitis (PSC):

Hereditary hemochromatosis:

Wilson disease:

Key Differentials — Acute Hepatitis and Drug/Other Causes

— HAV: fecal-oral, travel/food exposure, IgM anti-HAV positive, self-limited, no chronicity; vaccinate household contacts and post-exposure prophylaxis (Ig or vaccine)

— HBV acute: HBsAg + IgM anti-HBc; supportive care; antivirals if severe/fulminant

— HEV: water-borne; high mortality in pregnant women (third trimester); usually self-limited; can be chronic in immunocompromised

— HSV, CMV, EBV: especially in immunocompromised; mononucleosis-like syndrome

— Acetaminophen: dose-dependent; markedly elevated AST/ALT (often >1,000); N-acetylcysteine treatment

— Idiosyncratic: amoxicillin-clavulanate (most common antibiotic cause), isoniazid, methotrexate, statins (rare), nitrofurantoin, valproate

— Herbal/supplements: kava, green tea extract, anabolic steroids, garcinia, "detox" teas

— Pattern recognition: R-factor (ALT/ULN ÷ ALP/ULN); hepatocellular >5, cholestatic <2, mixed 2–5

— Massive AST/ALT spike (often >1,000) with rapid resolution after hemodynamic support

— Setting: shock, cardiac arrest, severe heart failure

— Hepatic vein thrombosis; classic triad: abdominal pain, ascites, hepatomegaly

— Hypercoagulable workup (JAK2, antiphospholipid, OCPs, pregnancy, MPN)

— Doppler ultrasound diagnostic

Board pearl: When transaminases exceed 1,000, the differential narrows sharply: acetaminophen toxicity, ischemic hepatitis, acute viral hepatitis, autoimmune hepatitis flare, and Budd-Chiari. Chronic HCV alone almost never produces this level of ALT.

Acute viral hepatitis:

Drug-induced liver injury (DILI):

Ischemic hepatitis ("shock liver"):

Budd-Chiari syndrome:

Granulomatous hepatitis: TB, sarcoidosis, brucellosis, drug-induced

Celiac disease: can cause mild unexplained transaminitis — check tTG-IgA

Thyroid disease: hypo- and hyperthyroidism cause transaminitis

Muscle disease (rhabdomyolysis): elevated AST > ALT, very high CK

HELLP syndrome in pregnancy: hemolysis, elevated LFTs, low platelets — pregnancy emergency

Secondary Prevention, Post-SVR Plan, and Long-Term Care

— No further HCV-specific follow-up needed

— Annual primary care visit; address general health

— HCC surveillance with ultrasound ± AFP every 6 months — lifelong

— EGD for variceal screening per Baveno criteria

— Continue management of portal hypertension (beta-blockers, etc.)

— Hepatology follow-up annually

— Annual HCV RNA testing (not antibody — antibody remains positive lifelong post-infection)

— Continue harm-reduction services, syringe exchange, MOUD

— Pre-exposure HIV counseling, PrEP if indicated

— Alcohol cessation — strongest modifiable accelerator of residual fibrosis and HCC

— Vaccinate: hepatitis A and B (if non-immune), influenza annually, pneumococcal (PCV20 or PCV15+PPSV23), COVID-19, Tdap, zoster (≥50)

— Weight management, glycemic control, lipid management — MASLD often coexists and continues fibrosis after cure

— Avoid hepatotoxins; review herbal/OTC products

— Coffee consumption (2–3 cups/day) associated with reduced HCC risk — reasonable to encourage

— Sexual transmission low in monogamous heterosexual couples — no specific precautions, no condom mandate

— Higher risk in MSM with traumatic practices — condoms recommended

— Don't share razors, toothbrushes, nail clippers

— No restrictions on kissing, hugging, sharing utensils, breastfeeding (unless cracked nipples)

Step 3 management: After SVR12, the durable habits of clinic — HCC surveillance every 6 months in cirrhotics for life, alcohol abstinence counseling, immunizations, and reinfection screening in at-risk patients — replace antiviral monitoring and define longitudinal HCV care.

After confirming SVR12, the patient is virologically cured, but care does not end. The long-term plan stratifies by fibrosis stage at the time of treatment.

If no cirrhosis (F0–F2) and no ongoing risk factors:

If advanced fibrosis or cirrhosis (F3–F4) at treatment:

If ongoing risk for reinfection (active IDU, MSM with high-risk practices, hemodialysis):

General secondary prevention measures:

Partner and household management:

Follow-Up, Monitoring Parameters, and Counseling Cadence

— Baseline labs, fibrosis staging, HBV/HIV screen, pregnancy test, medication reconciliation

— Patient education: 8-12 week course, importance of adherence, food/water requirements (gle/pib with food)

— Confirm insurance authorization (DAAs are costly; prior authorization usually required)

— Week 4: phone or in-person check — adherence, side effects, new medications. Labs only if cirrhotic, HIV, ribavirin use, or symptoms

— Week 8 or end of treatment: clinical check; HCV RNA optional (not predictive)

— Stop and call hepatology if ALT >10× ULN, jaundice, new symptoms, or significant DDI introduced

— 12 weeks after last dose: HCV RNA quantitative → SVR12 = cure

— Document cure in the chart prominently — affects future testing interpretation (antibody will remain positive forever)

— F0–F2, no risk: discharge from HCV-specific follow-up

— F3–F4: every 6 months ultrasound + AFP for HCC; annual hepatology

— Ongoing risk: annual HCV RNA

— Alcohol abstinence — biggest modifier; offer naltrexone/acamprosate, refer to AA, brief motivational interviewing

— Harm reduction for IDU: do not share needles, cookers, cottons, water; bleach cleaning; syringe-service program; offer MOUD (buprenorphine, methadone, naltrexone)

— Sexual health: HIV testing, PrEP for MSM at risk

— Vaccinations: HAV, HBV, annual influenza, pneumococcal per age, COVID, zoster

— Nutrition and weight: Mediterranean diet, exercise, weight loss if BMI elevated

— Coffee (2–3 cups/day): associated with reduced HCC and fibrosis progression

— Avoid hepatotoxins: limit acetaminophen to 2 g/day if cirrhotic; avoid NSAIDs in cirrhotics (renal/ascites/bleeding risk); review herbals

CCS pearl: In a longitudinal HCV CCS case, the high-value orders are alcohol counseling, HAV/HBV vaccination, FibroScan, HCV RNA at 12 weeks post-treatment, and (if cirrhotic) ultrasound + AFP every 6 months — these recur and accumulate scoring credit across simulated time.

Pre-treatment (week –4 to 0):

On-treatment:

Post-treatment:

Long-term follow-up by fibrosis stage:

Counseling at every contact:

Mental health: depression screening — fatigue, stigma, IDU comorbidity common; treat with SSRIs as needed.

Ethical, Legal, and Patient Safety Considerations

— Patient privacy is protected, but counseling patients to notify sexual partners and needle-sharing contacts is standard care

— Some health departments offer partner notification services — use them

— HCV status is not legally disclosed to employers, insurers, or family without patient consent (HIPAA)

— Discuss SVR rate, duration, drug-drug interactions (especially amiodarone, statins, anticonvulsants), HBV reactivation risk if HBsAg/anti-HBc positive, reinfection risk

— Document medication reconciliation explicitly

— Active substance use

— Alcohol use

— Adherence concerns based on social status

— Insurance restrictions requiring sobriety/specialist-only prescribing have been largely struck down; advocate for the patient

— Cost of DAAs has driven prior authorization; some states still impose fibrosis or sobriety restrictions — advocate, escalate

— Co-located HCV-MOUD-PrEP models in addiction clinics improve outcomes

— HBV reactivation under DAAs is a black-box warning — screen HBsAg + anti-HBc on every patient before starting

— Amiodarone + sofosbuvir → severe bradycardia/cardiac arrest — a medication-reconciliation safety check

— Polypharmacy in elderly — always run the regimen through the Liverpool HEP Drug Interactions checker

— Discharge from hospital with new HCV diagnosis — patients are frequently lost to follow-up; arrange explicit linkage with appointment scheduled and patient contacted within 1–2 weeks

— Post-incarceration release — high reinfection and loss-to-follow-up rates; warm hand-off to community provider is best practice

Board pearl: When a question presents an active drug user wanting HCV treatment, the correct action is prescribe DAAs and link to harm reduction/MOUD — not "defer until 6 months of sobriety." Sobriety mandates are not guideline-concordant.

Mandatory reporting: HCV is a nationally notifiable condition — laboratories and clinicians must report new HCV infections to state health departments per state-specific rules. Acute HCV requires faster reporting in most jurisdictions. Step 3 will test whether you know to report, not the specific case-form details.

Confidentiality and partner notification:

Informed consent for DAA therapy:

Withholding treatment is no longer ethically or clinically defensible based on:

Health systems and value-based care:

Patient safety pearls:

Transitions of care risks:

Occupational exposure (needle-stick): no post-exposure prophylaxis approved; test source and exposed worker baseline, HCV RNA at 3 and 6 weeks, antibody at 6 months; treat any seroconversion early.

High-Yield Associations and Rapid-Fire Clinical Facts

Key distinction: Anti-HCV is a lifelong marker of exposure; HCV RNA is the marker of active infection. After SVR, always order RNA, not antibody, to detect reinfection.

HCV genome: single-stranded positive-sense RNA, Flaviviridae family

No vaccine for HCV (envelope hypervariability); HAV and HBV both have vaccines — administer to every HCV patient who is non-immune

Universal one-time screening: all adults ≥18, all pregnancies (CDC, USPSTF 2020, ACOG)

Transmission: parenteral (IDU >> transfusion pre-1992) >> sexual (low in monogamous heterosexual) >> vertical (~6%, doubled with HIV)

Anti-HCV positive + HCV RNA negative = spontaneously cleared or treated; no active infection

Anti-HCV positive + HCV RNA positive = current infection — treat

HCV antibody persists for life — after SVR, use HCV RNA to detect reinfection, not antibody

SVR12 = undetectable HCV RNA 12 weeks after end of treatment = cure

First-line pangenotypic DAAs: glecaprevir/pibrentasvir 8 wk (with food) or sofosbuvir/velpatasvir 12 wk

Salvage: sofosbuvir/velpatasvir/voxilaprevir 12 wk

Decompensated cirrhosis → NO protease inhibitors (-previrs); use sof/vel ± ribavirin

Amiodarone + sofosbuvir = contraindicated (severe bradycardia)

HBV reactivation with DAAs — screen HBsAg + anti-HBc; prophylax if HBsAg+

Cirrhosis → lifelong HCC surveillance with ultrasound ± AFP every 6 months, even after SVR

Extrahepatic associations: cryoglobulinemia, MPGN, B-cell NHL, porphyria cutanea tarda, lichen planus, sicca syndrome, type 2 diabetes

MPGN with low C3/C4 + palpable purpura + arthralgias → HCV until proven otherwise

HCV/HIV: faster fibrosis — treat all

HCV in pregnancy: defer DAA; allow vaginal delivery and breastfeeding; test infant HCV RNA at 2–6 months

Ribavirin: teratogenic, Category X, hemolytic anemia; 6-month contraception both sexes

Coffee 2–3 cups/day reduces HCC risk

Alcohol is the largest modifiable accelerator of fibrosis — abstinence counseling at every visit

Active IDU is NOT a contraindication to treatment — pair with harm reduction and MOUD

Board Question Stem Patterns

Step 3 management: The single most common Step 3 distractor in HCV vignettes is choosing antibody to monitor cure or reinfection — always pick HCV RNA for any post-SVR question.

The screening vignette: 45-year-old asymptomatic adult presents for routine care, no risk factors mentioned. Next step? → HCV antibody (one-time universal screening).

The reflex testing vignette: HCV antibody positive in an asymptomatic patient. Next step? → HCV RNA quantitative.

The cleared infection vignette: anti-HCV positive, HCV RNA undetectable, never treated. Diagnosis? → Spontaneously cleared infection; no treatment, counsel re: reinfection, antibody will remain positive lifelong.

The cirrhosis screen vignette: Newly diagnosed HCV, platelets 110K, AST > ALT, FIB-4 4.2. Next step? → Elastography (FibroScan) and/or hepatology referral; assume advanced fibrosis; arrange HCC surveillance + EGD.

The drug-drug interaction trap: Patient on amiodarone for atrial fibrillation, starting DAAs. Best regimen? → Avoid sofosbuvir-based regimens (or hold amiodarone) — risk of severe bradycardia.

The HBV reactivation trap: Patient with HCV, HBsAg positive, starting DAAs. Next step? → Start entecavir or tenofovir prophylaxis before/with DAAs.

The decompensated cirrhosis trap: Child-Pugh B cirrhosis, ascites, jaundice. Treatment? → Sofosbuvir/velpatasvir + ribavirin × 12 weeks (avoid glecaprevir/pibrentasvir — PI).

The pregnancy vignette: Pregnant patient HCV RNA positive. Next step? → Defer DAA until postpartum; allow vaginal delivery and breastfeeding; test infant at 2–6 months.

The extrahepatic vignette: Patient with palpable purpura, arthralgias, glomerulonephritis, low C4. Diagnosis? → Mixed cryoglobulinemia from chronic HCV → check HCV RNA.

The IDU vignette: Active heroin user wants HCV treatment. Best response? → Treat with DAAs + link to MOUD/harm reduction; do not require sobriety.

The post-SVR HCC vignette: Cirrhotic patient achieved SVR12 three years ago, presents with weight loss and a 3-cm liver mass. Lesson? → Cirrhotics require lifelong every-6-month ultrasound ± AFP even after cure.

The SVR confirmation vignette: Patient finished 8 weeks of glecaprevir/pibrentasvir; HCV RNA undetectable at end of treatment. Next? → Repeat HCV RNA at 12 weeks post-treatment to confirm SVR12 — end-of-treatment response does not equal cure.

The reinfection vignette: Patient with prior SVR returns with elevated ALT and detectable HCV RNA. Diagnosis? → Reinfection (antibody will not have changed) → retreat.

One-Line Recap

High-yield bullet recap:

Board pearl: The Step 3 HCV story is screen everyone, treat almost everyone with DAAs, confirm cure with HCV RNA at 12 weeks, and surveil cirrhotics for HCC forever — paired with alcohol abstinence, vaccination, harm reduction, and recognition of extrahepatic disease (cryoglobulinemia, MPGN, NHL, PCT).

Chronic HCV is a universally screenable, virologically curable disease — every adult and every pregnancy should be tested with HCV antibody, every viremic patient should be offered pangenotypic DAA therapy, and every cirrhotic patient requires lifelong every-6-month HCC surveillance even after sustained virologic response.

Screening: universal one-time HCV antibody for all adults ≥18 and every pregnancy; reflex HCV RNA if positive. Antibody = exposure (lifelong); RNA = active infection.

Treatment: pangenotypic DAAs — glecaprevir/pibrentasvir × 8 weeks (with food) or sofosbuvir/velpatasvir × 12 weeks for treatment-naïve patients without or with compensated cirrhosis. Primary care can prescribe under simplified algorithms. Use sofosbuvir/velpatasvir ± ribavirin in decompensated cirrhosis (no protease inhibitors). Salvage = sof/vel/voxilaprevir. Screen for HBV reactivation and review drug interactions (amiodarone, statins, anticonvulsants, PPIs) before starting.

Cure: SVR12 = undetectable HCV RNA 12 weeks after the last dose; >95% achieve cure. Always confirm with RNA, not antibody.

Long-term follow-up: cirrhotics need lifelong ultrasound ± AFP every 6 months for HCC, variceal screening, and alcohol abstinence; ongoing-risk patients need annual HCV RNA for reinfection; everyone benefits from HAV/HBV vaccination, harm reduction, MOUD when indicated, and treatment of metabolic risk factors.